-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase I clinical trial of SYS6063 developed by the group to treat recurrent refractory systemic lupus erythematosus (SLE) has been officially launched at the first center in China.

Zhitongcaijing·08/11/2026 12:09:18
Listen to the news
Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase I clinical trial of SYS6063 developed by the group to treat recurrent refractory systemic lupus erythematosus (SLE) has been officially launched at the first center in China.